CTRI/2023/09/058149招募中3 期
A randomized, double-blind, placebo-controlled, parallel study to evaluate the efficacy and safety of Flavinergy on metabolic health of overweight adults. - NI
Sam Sabinsa Group Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Participants should be willing to give signed written informed consent.
- •2. Participants should be willing to comply with the requirements of the trial/study.
- •3. Male and Female participants aged between 25-55 years.
- •4. Subjects whose BMI lie between 25 to 29.99 kg/m2.
- •5. Subjects who meet any of the two criteria to be included in the study:
- •a) Triglyceride more than 160mg/dl
- •b) HDL Cholesterol less than 50 mg/dl in women and less than 40 mg/dl in men
- •c) LDL Cholesterol more than 120 mg/dl
- •d) Serum Total Cholesterol more than 200 mg/dl
- •6) Blood Pressure more than 130/90 mmHg without medication.
- •7) Fasting Blood Glucose more than 120 mg/dl without medication.
- •8) Ability to swallow and retain oral medications as per the protocol.
排除标准
- •1. Subjects who are taking any anti-obesity medication or weight reduction treatments including the herbal preparations.
- •2. Subjects with abnormal thyroid profile.
- •3. History of surgical procedures for weight loss.
- •4. Use of supplements, special diet or functional foods affecting carbohydrate and lipid metabolism during the study period.
- •5. History of chronic smoking and alcoholism.
- •6. Pregnant, lactating women and those not willing to follow a reliable and effective contraceptive measure during the study period.
研究者
相似试验
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group design study to evaluate the efficacy and safety of teriflunomide (HMR1726D) in reducing the frequency of relapses and delaying the accumulation of physical disability in subjects with multiple sclerosis with relapsesMultiple sclerosisMedDRA version: 12.0Level: PTClassification code 10028245Term: <Manually entered code. Term in E.1.1>EUCTR2004-000555-42-DKSanofi-aventis US, Inc1,080
进行中（未招募）
1 期
To evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's Disease (AD)MedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852Alzheimer's diseaseEUCTR2016-002976-28-ITOVARTIS PHARMA AG1,144
进行中（未招募）
1 期
Study in patients with primary Sjögren’s syndrome with the aim to assess safety, tolerability, pharmacokinetics (way the body absorbs, distributes, and gets rid of the drug) and preliminary efficacy of CDZ173Primary Sjögren's syndromeMedDRA version: 19.0Level: PTClassification code 10040767Term: Sjogren's syndromeSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2014-004616-12-DEovartis Pharma Services AG30
进行中（未招募）
1 期
Efficacy and safety of finerenone in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney diseaseType II Diabetes Mellitus and Diabetic Kidney DiseaseMedDRA version: 21.1Level: PTClassification code 10061835Term: Diabetic nephropathySystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2015-000950-39-ITBAYER AG12,800
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, parallel group, fixed-dose, 8-weektreatment, multi-center trial evaluating the dose effect relationship for efficacy and the safety of 3 oral doses of surinabant: 2.5, 5 and 10mg/day as an aid to smoking cessation in cigarette smokers - SURSMOKEAid to smoking cessation in cigarette smokersMedDRA version: 8.1Level: LLTClassification code 10057852Term: Nicotine dependenceEUCTR2006-005334-21-DEsanofi-aventis recherche et developpement805